Dashboard
Manage Tickers

IDYA IDEAYA Biosciences, Inc.

Nasdaq ideayabio.com


$ 32.49 $ 1.06 (3.37 %)    

Friday, 14-Nov-2025 13:31:12 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 609.93 $ 10.38 (1.73 %)
DIA $ 472.52 $ 1.10 (0.23 %)
SPY $ 672.83 $ 7.38 (1.11 %)
TLT $ 88.96 $ -0.83 (-0.92 %)
GLD $ 376.41 $ 3.57 (0.96 %)
$ 31.82
$ 31.47
$ 32.47 x 2
$ 32.43 x 101
$ 31.38 - $ 33.10
$ 13.45 - $ 33.64
961,476
na
2.79B
$ 0.70
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-18-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-23-2021 12-31-2020 10-K
21 11-12-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-12-2020 03-31-2020 10-Q
24 03-24-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

mizuho-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-46
Mizuho Maintains Outperform on IDEAYA Bios...
11/11/2025 14:03:56

Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target fr...

ideaya-biosciences-q3-eps-133-beats-047-estimate-sales-207834m-beat-5975m-estimate
IDEAYA Biosciences Q3 EPS $1.33 Beats $(0....
11/04/2025 11:29:43

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $(...

ideaya-biosciences-announces-73500-inducement-stock-options-granted-to-new-employees-under-nasdaq-listing-rule-5635c4
Ideaya Biosciences Announces 73,500 Induce...
10/31/2025 10:04:36

jp-morgan-maintains-overweight-on-ideaya-biosciences-raises-price-target-to-79
JP Morgan Maintains Overweight on IDEAYA B...
10/23/2025 15:53:36

JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from ...

goldman-sachs-maintains-neutral-on-ideaya-biosciences-raises-price-target-to-30
Goldman Sachs Maintains Neutral on IDEAYA ...
10/21/2025 18:01:49

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral and raises the price target ...

slb-to-rally-around-44-here-are-10-top-analyst-forecasts-for-tuesday
SLB To Rally Around 44%? Here Are 10 Top A...
10/21/2025 13:02:06

rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-41
RBC Capital Maintains Outperform on IDEAYA...
10/21/2025 12:09:40

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target...

btig-reiterates-buy-on-ideaya-biosciences-maintains-62-price-target
BTIG Reiterates Buy on IDEAYA Biosciences,...
10/21/2025 10:11:12

BTIG analyst Justin Zelin reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and maintains $62 price target.

ideaya-biosciences-presents-positive-clinical-data-from-ongoing-phase-2-optimum-09-trial-of-neoadjuvant-darovasertib-in-patients-with-primary-uveal-melanoma
IDEAYA Biosciences Presents Positive Clini...
10/20/2025 10:34:54

83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage57% (24/42) eye pre...

ideaya-biosciences-reports-median-overall-survival-results-from-phase-12-trial-optimum-01-of-darovasertib-in-combination-with-pfizers-crizotinib1x-for-metastatic-uveal-melanoma
Ideaya Biosciences Reports Median Overall ...
10/20/2025 10:12:50

Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 m...

guggenheim-initiates-coverage-on-ideaya-biosciences-with-buy-rating-announces-price-target-of-50
Guggenheim Initiates Coverage On IDEAYA Bi...
09/18/2025 13:00:12

Guggenheim analyst Paul Jeng initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and announces Price Ta...

buying-ideaya-might-be-the-wrong-idya-right-now
Buying IDEAYA Might Be The Wrong IDYA Righ...
09/16/2025 11:01:43

IDEAYA Stock's Adhishthana.com cycle signals prolonged weakness after a failed Cakra, with underperformance likely until Ma...

mizuho-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-44
Mizuho Maintains Outperform on IDEAYA Bios...
09/12/2025 14:04:16

Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target fr...

alibaba-to-rally-around-35-here-are-10-top-analyst-forecasts-for-tuesday
Alibaba To Rally Around 35%? Here Are 10 T...
09/09/2025 14:11:09

rbc-capital-maintains-outperform-on-ideaya-biosciences-raises-price-target-to-38
RBC Capital Maintains Outperform on IDEAYA...
09/09/2025 13:25:57

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target...

cantor-fitzgerald-reiterates-overweight-on-ideaya-biosciencesto-overweight
Cantor Fitzgerald Reiterates Overweight on...
09/09/2025 13:15:58

Cantor Fitzgerald analyst Li Watsek reiterates IDEAYA Biosciences (NASDAQ:IDYA) from Overweight to Overweight.

stephens--co-reiterates-overweight-on-ideaya-biosciences-maintains-45-price-target
Stephens & Co. Reiterates Overweight on ID...
09/09/2025 13:11:34

Stephens & Co. analyst Sudan Loganathan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and maintains $45 ...

jmp-securities-maintains-market-outperform-on-ideaya-biosciences-raises-price-target-to-45
JMP Securities Maintains Market Outperform...
09/08/2025 14:10:24

JMP Securities analyst Silvan Tuerkcan maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and raises the pr...

ideaya-biosciences-reports-data-from-phase-12-combination-trial-of-ide397-and-trodelvy-in-mtap-deletion-urothelial-cancer
IDEAYA Biosciences Reports Data From Phase...
09/08/2025 12:07:50

Overall response rate (ORR) of 57% (4/7; 3cPR+1uPR) in patients treated with a combination of 30 mg IDE397 plus 7.5mg/kg Trodel...

ideaya-biosciences-reports-tumor-shrinkage-and-vision-gains-in-eye-cancer-trial
IDEAYA Biosciences Reports Tumor Shrinkage...
09/08/2025 10:03:07

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, will present positive interim data at th...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION